Immunosuppression under trial : proceedings of the 31st Conference on Transplantation and Clinical Immunology, 3-4 June, 1999
Author(s)
Bibliographic Information
Immunosuppression under trial : proceedings of the 31st Conference on Transplantation and Clinical Immunology, 3-4 June, 1999
（Transplantation and clinical immunology : Symposia fondation marcel mérieux, v. 31）
Kluwer Academic Publsihers, c1999
- hb : alk. paper
Available at 2 libraries
Description and Table of Contents
Description
Immunosuppression in solid organ transplantation is experiencing a worldwide revival since new drugs are now available in the late-1990s and others are under development. In order to contribute to the design of future strategies, a critical approach of surrogate endpoints is given and long-term side effects are analyzed, together with the impact of non-compliance, quality-of-life and economical parameters. In this book, international specialists have set up the scientific rationale and provided new bases for further immunosuppressive strategies.
Table of Contents
- Part 1 Setting the stages in clinical trials: Current results as reference for future improvements in immunosuppression, G. Opelz, et al
- Rationale of clinical trials from the physician, C. Legendre
- Minimal standards for reporting clinical trial results in transplantation, B.L. Kasiske, H. Chakkera
- Methodological approach of clinical trials for renal transplantation, P. Landais, J.P. Jais. Part 2 Is acute rejection an appropriate surrogate marker?: Surrogate endpoints for clinical trials in renal transplantation, B.L. Kasiske
- Is acute rejection an appropriate surrogate marker for clinical trials in liver transplantation? O. Farges
- The success of clinical immunosuppressive trials in heart transplantation - the early detection of acute rejection, M. Antoine. Part 3 Towards long-term end-points: Factors influencing long-term allograft survival, C. Van Buren. Part 4 Can we minimize the long-term side-effects?: Patients' appraisal of side-effects in quality of life assessments of immunosuppressive regimens, P. Moons, et al
- Cardiovascular complications after renal transplantation, V. Schwenger, et al
- Strategies to minimize nephrotoxicity associated with calcineurin inhibitors, J. Alsina
- Diabetogenic effect of immunosuppressive drugs, X. Martin
- Can we minimize long-term side effects of immunosuppressive drugs on lipid metabolism? Z.A. Massy
- Can we minimize the long-term side-effects of immunosuppressive drugs in pediatric patients? B. Tonshoff, et al. Part 5 Strategies: Induction therapy, D. Abramowicz, K.M. Wissing
- Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence - randomised comparison of two cyclosporin regimens, J. Dantal, et al
- Immunosuppression in composite tissue transplantation, J.-M. Dubernard, et al
- The search for immunosuppressive synergy, C. Van Buren
- Economic analysis of immunosuppression in transplantation - a review of recent studies in liver and kidney transplantation, J. Hutton. Part 6 Clinical trials for at-risk situations
- Questions raised by the exclusion of "at risk" conditions from current trials in organ transplantation, J.P. Revillard, et al.
by "Nielsen BookData"